Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.38 |
| ▸ | HTR6 | P50406 | 12/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3907646 | 0.79 | HTR2C (0.53) | PNMTHTR6ADRA2AADRA2BADRA2C | |
| SCHEMBL3902011 | 0.77 | ESR2 (0.44) | — | |
| SCHEMBL10703537 | 0.74 | PKM (0.48) | HTR6 | |
| SCHEMBL3901830 | 0.72 | HTR6 (0.38) | PNMTHTR6ADRA2AADRA2BADRA2C | |
| SCHEMBL10704500 | 0.72 | HTR2C (0.57) | PNMTHTR6 | |
| SCHEMBL5181064 | 0.72 | CNR1 (0.39) | PNMTHTR6ADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL3900202 | 0.72 | CNR1 (0.38) | PNMTHTR6ADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL5194614 | 0.72 | CNR1 (0.38) | PNMTHTR6 | |
| SCHEMBL5479184 | 0.71 | DRD2 (0.37) | HTR6ALK | |
| SCHEMBL5182635 | 0.70 | HTR6 (0.43) | PNMTHTR6ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504392-B2 | 2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use | GLAXO GROUP LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20080269197-A1 | antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
| EP-1511727-B1 | AROMATIC SULFONES AND THEIR MEDICAL USE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| EP-1511727-A2 | AROMATIC SULFONES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003099786-A2 | AROMATIC SULFONES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269197-A1 | antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia | SIGMAR1, CBR3, CBR1 | PNMT 243/4885HTR6 103/4885ADRA2A 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.